Apollo Hospitals Enterprise

Valuation risk: PE 61.39 leaves minimal margin of safety if earnings growth slows or disappoints.

Margin gap: Consolidated operating margins (14.9–15.5%) significantly lag standalone margins (24–25%), raising questions about profitability of expansion segments.

Foreign capital concentration: FII holding at 41.5% versus promoter stake at 28% creates exposure to international fund flow volatility.

Regulatory pressure: Verify impact of healthcare pricing regulation, reimbursement policy changes, and labor cost mandates on consolidated margins.

Revenue scaling: consolidated revenue grew 11.7% year-on-year (₹6,303.5 Cr Sep 2025 to ₹7,043.5 Cr Jun 2026) with profit growth accelerating to 23.5%.

Diagnostic and digital health expansion cited in description—verify market opportunity, rollout status, revenue contribution, and margin profile.

Standalone segment stable at 24–25% OPM over 9 months (Dec 2025 25.11%, Mar 2026 24.42%, Jun 2026 24.71%) provides high-margin operational base.

ROE of 21.95% signals efficient capital deployment; verify reinvestment rate and capex allocation strategy.